Previous studies have shown that CD141+ cDC1 numbers and functions in the tumor are predictive of patient outcome1,3,36, prompting us to assess whether changes in CD141+ cDC1s in the BM prior to treatment or resection were also predictive of response to therapy. The gene discussed is THBD; the disease is neoplasm.